IRA will re­duce out-of-pock­et spend­ing among some Part D en­rollees by $7.4B in 2025, HHS re­port says

The In­fla­tion Re­duc­tion Act could low­er out-of-pock­et costs by around $7.4 bil­lion in 2025 for more than a third of all Amer­i­cans en­rolled in Medicare Part D, ac­cord­ing to a new re­port from the De­part­ment of Health and Hu­man Ser­vices’ Of­fice of Health Pol­i­cy.

The 41-page re­search pa­per, re­leased Thurs­day, mod­eled some of the IRA’s drug-re­lat­ed pro­vi­sions for 2024 and 2025. The pro­vi­sions, among oth­ers, in­clude the $2,000 a year out-of-pock­et spend­ing lim­it for Part D per year (in­dexed to in­fla­tion), a $35 per-month lim­it on cov­ered in­sulin prod­ucts, elim­i­nat­ing cost shar­ing on ACIP-rec­om­mend­ed adult vac­cines and ex­pan­sion of the low-in­come sub­sidy (LIS).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER